Evidence map›Paper›PMID 39713388›Full record

ArticlebioRxiv : the preprint server for biology2024

Humoral correlate of vaccine-mediated protection from tuberculosis identified in humans and non-human primates.

Natasha S Kelkar, Nicholas C Curtis, Timothy P Lahey, Wendy Wieland-Alter, Jason E Stout, Erica C Larson, Solomon Jauro, Charles A Scanga, Patricia A Darrah, Mario Roederer and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Natasha S KelkarDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Nicholas C CurtisThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Timothy P LaheyDepartment of Medicine, University of Vermont Larner College of Medicine, Burlington, VT, USA.
Wendy Wieland-AlterGeisel School of Medicine at Dartmouth, 1 Medical Center Drive, Lebanon, NH, USA.
Jason E StoutDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
Erica C LarsonDepartment of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Solomon JauroDepartment of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Charles A ScangaDepartment of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Patricia A DarrahVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Bethesda, MD, USA.
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Bethesda, MD, USA.
Robert A SederVaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Bethesda, MD, USA.
C Fordham von ReynDartmouth International Vaccine Initiative, Geisel School of Medicine, 1 Medical Center Drive, Lebanon, NH, USA.
Jiwon LeeThayer School of Engineering, Dartmouth College, Hanover, NH, USA.ORCID 0000-0001-7835-3621
Margaret E AckermanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.ORCID 0000-0002-4253-3476

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Understanding the role of RNA-binding protein mutations in cancerP20GM113132 · NIGMS · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2016 to 2025
$25.9M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Practices CoreUC7AI180311 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI William Paul Duprex · 2023 to 2026
$13.2M
Preventing TB with intravenous BCG in SIV-infected macaquesR01AI155345 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCANGA, CHARLES A. · 2021 to 2025
$4.2M
The Impact of Pre-exisiting SIV on Host Immunity to M tuberculosis in MacaquesR01AI111815 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCANGA, CHARLES A. · 2015 to 2019
$3.8M
Re-educating T cell-mediated immunity in SIV by modulating metabolic pathwaysK01OD033539 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LARSON, ERICA CHRISTINE · 2022 to 2024
$571k
NIAID NIH HHS N01 AI040082NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI111815NIAID NIH HHS R01 AI155345NIAID NIH HHS U24 AI126683NIAID NIH HHS UC7 AI180311NIGMS NIH HHS P20 GM113132NIH HHS K01 OD033539
6 · The paper itself

Abstract

Development of an effective tuberculosis (TB) vaccine has been challenged by incomplete understanding of specific factors that provide protection against

Indexed as

AntibodyCorrelates of ProtectionEfficacy trialHumoral immunityTuberculosisVaccine

Identifiers

PMID39713388
PMCPMC11661070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.